AbbVie Inc vs Carvana Co — how do they compare? AbbVie Inc trades at $249.84 (market cap $441.94B), while Carvana Co trades at $71.97 (market cap $79.17B). The key difference: AbbVie Inc is far larger — about 5.6× Carvana Co's market cap, and AbbVie Inc pays a 2.77% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| ABBV | CVNA | |
|---|---|---|
Market Cap | $441.94B | $79.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $95.69 |
52-Week Low | $197.38 | $56.27 |
Enterprise Value | $506.19B | $81.65B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →